No Data
No Data
Beijing Science Sun Pharmaceutical (300485.SZ): The main products are biopharmaceuticals, involving three major fields of medication for cardiovascular diseases, immune diseases (anti-tumor) and nervous system diseases.
Beijing Science Sun Pharmaceutical (300485.SZ) stated on the investor interaction platform that the company's leading products are biopharmaceutical products involving three major therapeutic areas: cardiovascular and cerebrovascular diseases, immunological diseases (anti-tumor) and neurological diseases. The company is the original drafting unit of national drug standards for five varieties of products, including fibrinolytic enzyme, fibrinolytic enzyme injection, injection fibrinolytic enzyme, thinsetide injection, and deoxyribonucleoside sodium injection; fibrinolytic enzyme injection, thinsetide injection and 100mg injection of thymopeptide are the first drugs to be produced in China; monosialotetrahexosylganglioside sodium injection.
Saisheng Pharmaceutical (300485.SZ): The company is not involved in the vaccine business
Gelonghui, May 27 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company's shareholding company Luzhu Biotech is a company whose main research direction is human vaccines and therapeutic bifunctional antibody drugs. Please check its official and statutory disclosure information websites for relevant information. The company is not involved in the vaccine business.
Saisheng Pharmaceutical (300485.SZ) plans to pay 0.22 yuan for 10 shares to be deducted from interest on May 29
Saisheng Pharmaceutical (300485.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Saisheng Pharmaceutical (300485.SZ): It has genetic engineering and biological extraction technology, and can be applied to synthetic biology. Currently, the company is not involved in this business
Gelonghui, May 8 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company has genetic engineering and biological extraction technology, which can be applied to synthetic biology. Currently, the company is not involved in this business. Among the investment projects initiated by the company, 3 companies involved synthetic biology: Shanxi Kaisheng Biotechnology Co., Ltd., Chengdu Yatu Biotechnology Co., Ltd., and Like Times (Wuhan) Biotechnology Co., Ltd.
Saisheng Pharmaceutical (300485.SZ): Net loss of 190 million yuan in the first quarter turned into a year-on-year loss
On April 25, Gelonghui | Saisheng Pharmaceutical (300485.SZ) released its first quarter report. Operating revenue was 110 million yuan, down 17.46% year on year, net loss was 190 million yuan, turning loss year on year. After deducting non-net profit of 15.1578 million yuan, up 383.81% year on year, and basic earnings per share -0.3957 yuan.
Saisheng Pharmaceutical (300485.SZ): As of April 10, 2024, the number of shareholders of the company was 31,397
Gelonghui, April 12 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 31,397.
No Data